EXAS Earnings Prediction
The chart below shows how EXAS performed 10 days before and after its earnings report, based on data from the past quarters. Typically, EXAS sees a +2.66% change in stock price 10 days leading up to the earnings, and a +1.69% change 10 days following the report. On the earnings day itself, the stock moves by -0.19%. This data can give you a slight idea of what to expect for the next quarter's release.
EXAS Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
713.42M
10.29%
0.67%
Gross Margin
60.17%
-0.63%
-12.65%
Operating Margin
-5.35%
-49.00%
83.22%
Net Margin
-121.19%
1475.94%
2144.26%
EPS
-4.67
-1629.63%
2123.81%
No Data Available
EXAS Earnings Analysis
Exact Sciences Corp Corporation (EXAS.O) Earnings Conference Call
Positive
Cancer Test Results Impact: More than 4.6 million results delivered to patients with cancer tests in 2024, showcasing the company's extensive reach and impact.
Core Revenue Growth: Core revenue grew by 11%, indicating strong business performance and demand for services.
Cost Management Success: Non-GAAP operating expenses grew only 2%, leading to a significant 48% increase in EBITDA, demonstrating effective cost management.
Strong Financial Health: Free cash flow more than doubled, ending the year with $1.04 billion in cash and securities, reflecting strong financial health.
Cologuard Plus Approval: FDA approval and Medicare pricing secured for Cologuard Plus, enhancing the company's product offerings in colon cancer screening.
Screening Revenue Increase: Screening revenue increased by 14% to $553 million, driven by increased adoption of Cologuard among providers and health systems.
International Oncotype DX Adoption: Oncotype DX adoption increased internationally, contributing to Precision Oncology revenue growth.
EBITDA Margin Expansion: Adjusted EBITDA margin expanded nearly 300 basis points, indicating improved profitability and operational efficiency.
Cologuard Patient Growth: The number of eligible patients for Cologuard tests is expected to grow by 30% to 2 million, setting the stage for future growth.
Innovative Product Pipeline: Exact Sciences is positioned to launch three new tests in 2025, indicating a strong pipeline of innovative products.
Clinical Evidence Support: Clinical evidence for Oncodetect and Cancerguard supports their effectiveness, enhancing the company's credibility in the market.
Negative
Impairment Charge Impact: The company recognized an $830 million noncash impairment charge related to the Thrive acquisition, indicating significant financial strain and a potential miscalculation in the acquisition's value.
Precision Oncology Revenue Stagnation: Precision Oncology revenue growth was only slight, increasing to $161 million, suggesting stagnation in this segment compared to the more robust growth in Screening revenue.
Screening Revenue Decline: The first quarter of 2025 is expected to see a sequential decline in Screening revenue due to seasonal trends, which could indicate vulnerability in revenue stability during certain periods.
Cologuard Plus Revenue Outlook: The company anticipates that growth from Cologuard Plus will phase in over the next 18 to 24 months, suggesting a slow ramp-up in revenue from this new product rather than immediate impact.
Precision Oncology Revenue Challenges: The guidance for Precision Oncology revenue growth is only 5% for the full year, which may reflect challenges in expanding this segment compared to the more dynamic Screening revenue growth.
EXAS FAQs
How does EXAS typically perform around its earnings report dates?
Is Exact Sciences Corp (EXAS) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
EXAS Earning Call Sentiment
Exact Sciences (EXAS) Q4 2024 Earnings Call Transcript
EXAS.O
3.11%Positive
The earnings call presents a positive outlook with strong financial performance, including 11% revenue growth and significant margin expansion. The launch of Cologuard Plus and new tests are expected to drive growth, and the company is confident in its 2025 guidance. However, risks such as regulatory challenges and market competition exist. The Q&A section reflects optimism about growth drivers and strategic execution. While the lack of a share repurchase or dividend program is noted, the overall sentiment remains positive, likely leading to a stock price increase of 2% to 8%.
